Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis-dependent diseases.

J Folkman1

  • 1Department of Surgery, Harvard Medical School, Boston, MA, USA.

Seminars in Oncology
|December 12, 2001
PubMed
Summary
This summary is machine-generated.

Angiogenesis inhibitors show promise in treating blood cancers like multiple myeloma, even when other therapies fail. These drugs, which block new blood vessel growth, are being explored alone and with standard treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Matrigel cytometry: a novel method for quantifying angiogenesis in vivo.

Journal of immunological methods·2008
Same author

Is oncogene addiction angiogenesis-dependent?

Cold Spring Harbor symposia on quantitative biology·2006
Same author

Endostatin therapy reveals a U-shaped curve for antitumor activity.

Cancer gene therapy·2006
Same author

Long-term remission of Crohn's disease treated with thalidomide: a seminal case report.

Angiogenesis·2003
Same author

Angiogenesis and proteins of the hemostatic system.

Journal of thrombosis and haemostasis : JTH·2003
Same author

The role of angiostatin in the spontaneous bone and prostate cancers of pet dogs.

Biochemical and biophysical research communications·2002

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Leukemias and other hematologic malignancies exhibit dependency on angiogenesis.
  • Angiogenesis inhibitors represent a potential therapeutic strategy for these hematologic diseases.

Purpose of the Study:

  • To present evidence supporting the use of angiogenesis inhibitors in hematologic diseases.
  • To highlight the role of antiangiogenic activity in thalidomide's efficacy for multiple myeloma.

Main Methods:

  • Review of experimental and clinical data on angiogenesis inhibitors.
  • Examination of thalidomide's mechanism of action in multiple myeloma.

Main Results:

  • Thalidomide demonstrates efficacy in multiple myeloma, partly through antiangiogenic mechanisms.

Related Experiment Videos

  • Angiogenesis inhibitors are currently used in clinical trials for various cancers, often combined with chemotherapy or radiotherapy.

    • Conclusions:

    • Angiogenesis inhibitors can be effective as monotherapy when conventional treatments fail.
    • Combination therapies involving angiogenesis inhibitors are increasingly utilized in cancer treatment.